The fund primarily invests in growth stocks of small cap companies. Effective close of business on October 27, 2023, abrdn, Inc. assumed responsibility for the management of the fund, formerly known as Tekla Life Sciences Investors. The fund provides exposure to emerging life sciences companies with potential for significant growth in biotechnology products and services driven by aging demographics and adoption of new medical innovations.
Cyborg Score Rationale
As of March 31, 2026, the fund showed 1-year NAV returns of 52.59% but market price returns of 45.45%. The strong year-over-year performance is tempered by the fund's non-diversified strategy focusing on small-cap life sciences companies, which carries concentrated sector risk. Recent management transition to abrdn provides institutional backing and professional oversight.
Top Insights
Non-diversified closed-end fund structure with concentrated exposure to small-cap life sciences companies enables potential for significant capital appreciation but carries higher volatility
Strong 1-year performance (52.59% NAV return as of March 2026) reflects positive market conditions for biotechnology and healthcare innovation sectors
Management transition to abrdn in October 2023 brought experienced institutional asset management expertise to the fund
Fund trades on NYSE allowing public investors direct access to life sciences sector with dividend distributions ($0.56 per share ex-date May 21, 2026)
Named Competitors
abrdn Healthcare Investors — Closed-end healthcare fund with similar life sciences investment focus
abrdn Healthcare Opportunities Fund — Closed-end healthcare opportunities fund
abrdn World Healthcare Fund — Global healthcare-focused closed-end fund
Recent Developments
(October 2023) Management transition: abrdn, Inc. assumed responsibility for the fund from Tekla Capital Management, LLC
(March 2026) Q1 2026 performance showed 52.59% NAV return year-to-date and 45.45% market price return
(May 2026) Fund announced cash dividend of $0.56 with ex-date of May 21, 2026
Open the full interactive abrdn Life Sciences Investors report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.